XTX Topco Ltd Takes $1.30 Million Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• XTX Topco Ltd has acquired 19,342 shares of TransMedics Group, Inc., valued at approximately $1.3 million, reflecting a 0.06% ownership stake.
• Several institutional investors, including OneDigital Investment Advisors LLC and New York State Teachers Retirement System, significantly increased their positions in TransMedics Group during the first quarter of the year.
• TransMedics Group recently reported strong earnings, with an EPS of $0.92, exceeding analyst estimates, and year-over-year revenue growth of 37.7%.

XTX Topco Ltd purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 19,342 shares of the company's stock, valued at approximately $1,301,000. XTX Topco Ltd owned approximately 0.06% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. NBC Securities Inc. bought a new stake in TransMedics Group in the 1st quarter valued at $25,000. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group during the fourth quarter valued at about $31,000. Hager Investment Management Services LLC grew its stake in TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the period. CWM LLC raised its stake in TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after acquiring an additional 155 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after acquiring an additional 1,324 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on TMDX shares. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Canaccord Genuity Group raised their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Finally, Oppenheimer raised their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $123.00.

Insider Activity at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director owned 2,866 shares in the company, valued at approximately $362,405.70. The trade was a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,418 shares of company stock worth $1,512,613. Insiders own 7.00% of the company's stock.

TransMedics Group Stock Performance

TransMedics Group stock traded down $6.94 during mid-day trading on Wednesday, hitting $118.80. The company had a trading volume of 1,168,016 shares, compared to its average volume of 1,362,367. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 61.55 and a beta of 2.09. The company's fifty day moving average is $124.54 and its 200-day moving average is $96.21. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same quarter in the prior year, the company earned $0.35 EPS. TransMedics Group's revenue was up 37.7% compared to the same quarter last year. Equities research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.